Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

itation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The top-line efficacy, safety and tolerability data for pirfenidone reported in this press release are from analyses of the highest areas of interest to the company based on the prior clinical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently intends to submit in support of its NDA and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made which may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its regulatory submissions in the United States and Europe. These analyses and observations will be included in a presentation of the CAPACITY data that the company expects to make at the American Thoracic Society (ATS) in the second quarter of 2009, and/or in a scientific publication.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 College of DuPage students ... gaining invaluable real-world experiences while serving biophysics internships at ... The students will be working as a part ... at IIT. The internship came about from a ... Physics; Dr. Kathy Finan , Biology; and Dr. ...
(Date:7/1/2015)... ... ... It is now possible to separate two common disorders: post-traumatic stress disorder ... according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and University of ... to be the largest brain imaging study ever, will be published on July 1, ...
(Date:7/1/2015)... PALO ALTO, Calif. , July 1, 2015 ... company focused on the development of groundbreaking drugs ... sclerosis (ALS), announced today that Robert G. ... Research Center at Sutter Health,s California Pacific Medical ... from The ALS Association for $1.5 million to ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... On Thursday, October,18, 2007, Wyeth (NYSE: WYE ... The Company will hold a one-hour conference call with,research ... 2006. Interested,investors and others may listen to the call ... which may be accessed by visiting our website,at ...
... Overall Survival and Risk ... Metastasizing to Distant Sites, REHOVOT, Israel and NEW YORK, ... global leader in the field of,microRNA and RNAi, announced today ... leverage the significant potential of microRNA,profiles to develop a diagnostic ...
... KONG, Sept. 7 /Xinhua-PRNewswire-FirstCall/ -- China Technology,Development ... "Company") today,announced the new business strategy of ... government commitment to significantly increase China,s,use of ... rising energy demand,CTDC strongly believes the new ...
Cached Biology Technology:NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5China Technology Announces Entry to the Solar Energy Sector 2China Technology Announces Entry to the Solar Energy Sector 3
(Date:6/23/2015)... 2015   Valencell, a leader in ... a recent study that illustrates its PerformTek biometric ... activity. In a study conducted at Valencell,s Biometric ... the Apple Watch against a chest strap – ... activity. The study demonstrated that Valencell,s biometric technology ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... ON January 27, 2014 Cancer is the ... for about 30% of all deaths, according to the ... and effective drugs, it remains extremely difficult to develop ... looked at how to leverage current experimental therapies, in ...
... from Warwick Medical School have discovered a critical point of ... cell in the human body. The study, published today ... system is a key target for cancer drugs and, as ... be made. The tracks of this so called ,railway, are ...
... researchers have discovered the process by which high-density ... becomes dysfunctional, loses its cardio-protective properties, and instead ... hardening of the arteries. Their research was published ... . The beneficial and cardio-protective properties of ...
Cached Biology News:Ottawa researchers discover new combination therapy to kill cancer 2Cracks in the cellular transport system can be key to a new generation of cancer therapies 2Cleveland Clinic researchers discover process that turns 'good cholesterol' bad 2
Request Info...
... Kit Contains the following: , Coated Capture Antibody: ... , Wash/Sample Diluent: 300 mL of 2X concentrate ... 10 microg lyophilized peptide , Lyophilized Standard Diluent: ... 50X concentrate , Secondary Antibody-HRP: 30 microL of ...
carnitine deficiency-associated gene expressed in ventricle 1...
... Clone/PAD: ZMD.471. Immunogen: Synthetic peptide ... the mouse junctophilin-1. Specificity: Specific ... Mouse (positive controls: mouse brain and ... and skeletal muscle tissues). Applications: ...
Biology Products: